Novo Nordisk CEO Lars Jorgensen is about to testify earlier than the Senate Committee on Well being, Training, Labor and Pensions (HELP), which Sanders chairs, in a listening to subsequent week specializing in U.S. costs for its extensively standard Ozempic and weight-loss drug Wegovy.
- Up to date On Sep 18, 2024 at 02:42 PM IST
Learn by:
100 Trade Professionals
Learn by
100 Trade Professionals
Bengaluru: U.S. Senator <a id=” captionrendered=”1″ data-src=”https://etimg.etb2bimg.com/photograph/113453521.cms” top=”442″ href=”/tag/bernie+sanders” keywordseo=”Bernie-Sanders” loading=”keen” supply=”key phrases” src=”https://img.etb2bimg.com/information/cp/upload-1716881542-ethealthworld.webp” kind=”Common” weightage=”20″ width=”590″>Bernie Sanders stated on Tuesday he obtained affirmation from main generic pharmaceutical corporations that they might promote copycat variations of Novo Nordisk‘s diabetes drug Ozempic for lower than $100 a month. WHY IT’S IMPORTANT
Novo Nordisk CEO Lars Jorgensen is about to testify earlier than the Senate Committee on Well being, Training, Labor and Pensions (HELP), which Sanders chairs, in a listening to subsequent week specializing in U.S. costs for its extensively standard Ozempic and weight-loss drug Wegovy.
KEY QUOTE
Sanders stated he spoke to the chief executives of a number of main generic drugmakers over the previous few months.
“They’ve studied the matter and so they inform me that they’ll promote a generic model of Ozempic, the very same drug that Novo Nordisk is manufacturing, to People for lower than $100 monthly,” he stated.
Sanders didn’t title the businesses to which he spoke. Ozempic’s patent will not be set to run out in america till 2032.
CONTEXT
Ozempic, which has the identical energetic ingredient as Wegovy and is used off-label for weight reduction, belongs to the favored GLP-1 class, which has seen overwhelming demand in america.
Some analysts have forecast the overall marketplace for weight-loss medication to succeed in $150 billion by the early 2030s.
Nevertheless, this comes amid criticism from lawmakers over the excessive prices related to these drugs.
BY THE NUMBERS
A month’s provide of Novo’s Ozempic carries a U.S. checklist value of $935.77 whereas Wegovy lists for $1,349.02 monthly, based on the drugmaker’s web site, though most customers pay much less.
(Reporting by Mariam Sunny in Bengaluru; Modifying by Krishna Chandra Eluri)
- Revealed On Sep 18, 2024 at 02:38 PM IST
Be a part of the group of 2M+ {industry} professionals
Subscribe to our publication to get newest insights & evaluation.
Obtain ETHealthworld App
- Get Realtime updates
- Save your favorite articles
Scan to obtain App
